MCM
DGX icon

MidAtlantic Capital Management’s Quest Diagnostics DGX Stock Holding History

MidAtlantic Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35
Closed -$6.07K – 116
2025
Q4 		$6.07K Buy
+35
New +$6.37K ﹤0.01% 215
2025
Q1 		– Sell
-67
Closed -$10.1K – 115
2024
Q4 		$10.1K Hold
67
– – 0.01% 208
2024
Q3 		$10.4K Hold
67
– – 0.01% 205
2024
Q2 		$9.17K Sell
67
-4
-6% -$548 0.01% 195
2024
Q1 		$9.45K Sell
71
-15
-17% -$1.95K 0.01% 206
2023
Q4 		$11.9K Buy
+86
New +$11.3K 0.01% 195

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

MidAtlantic Capital Management's DGX Position: Q1 2026 in Review

MidAtlantic Capital Management sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 35 shares — an estimated $6.07K sold.

MidAtlantic Capital Management first reported a position in DGX in Q4 2023 and held it in 6 quarters. The position peaked at $11.9K in Q4 2023. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • MidAtlantic Capital Management reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • MidAtlantic Capital Management sold 35 Quest Diagnostics shares in Q1 2026, an estimated $6.07K.
  • MidAtlantic Capital Management first reported a position in Quest Diagnostics in Q4 2023 and held it in 6 quarters.
  • MidAtlantic Capital Management's Quest Diagnostics position peaked at $11.9K in Q4 2023.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on MidAtlantic Capital Management's 13F filing for Q1 2026, filed 8 May 2026.